Related coverage linked through entity extraction aliases.
Aug 23, 2026
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
Aug 17, 2026
A CREST-2 substudy presented at ISC 2026 found that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. Cognitive decline occurred only in patients who experienced a stroke, with no differences between revascularization and medical therapy alone.
Aug 08, 2026
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Jul 01, 2026
Cadrenal Therapeutics received FDA guidance for a pivotal Phase 3 trial of CAD-1005 in HIT after an End-of-Phase 2 meeting. Phase 2 data showed a >25% absolute reduction in thrombotic events. The company also plans a Phase 2a trial in cardiac surgery-associated AKI.
Jun 30, 2026
Recent studies show that resistance training lowers cardiovascular disease risk in women, muscular strength is tied to lower mortality in older women, and both weekend warrior and regular exercise patterns reduce mortality in patients with hypertension.
Jul 26, 2026
Adjunct intra-arterial alteplase after thrombectomy improved 90-day functional recovery in LVO stroke (57.5% vs 42.5%). Headache occurs in 46% of hemorrhagic stroke patients; only 21.8% of stroke/TBI patients receive inpatient rehab.
Jul 06, 2026
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
May 03, 2026
A systematic review found strong FAERS signals linking labetalol to rare liver injury, while a case report describes hyperacute liver failure from high-dose atorvastatin that resolved after discontinuation.
May 01, 2026
Boston Scientific exceeded Q4 2025 guidance with 12.7% organic revenue growth and over $20 billion in annual sales. The company outlined a 2026 outlook of 10-11% organic growth, while shares fell 17.6% after earnings due to supply-chain issues and EP share losses.
Jul 14, 2026
First-line pulsed field ablation achieved 56% vs 30% success with drugs in persistent AFib (HR 0.46). Device-related serious adverse events occurred in 5.1%. Results published in NEJM.
Jul 05, 2026
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company specializing in True Human monoclonal antibodies. Pipeline candidates include Natrunix and Hutrukin. The company is held by small-cap value ETFs.
Jun 08, 2026
UKCA approval was granted for the LVOne stroke blood test, piloting with London Ambulance Service. A phase 2 trial showed LT 3001 is safe up to 24 hours post-stroke; 'leaky core' imaging links barrier disruption to worse outcomes.
Jul 24, 2026
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
Jul 23, 2026
A Cochrane review finds exercise for hip osteoarthritis reduces pain by 7 points on a 100-point scale, below the 12-point threshold for noticeable benefit. A survey shows 76% of physical therapy patients skip home exercises, citing forgetfulness and time constraints. A study reports only 22% of stroke and brain injury survivors receive intensive inpatient rehab, with disparities by race, insurance, and income.
Jul 13, 2026
A study finds that white matter disease detected on CT scans signals a higher risk for stroke or dementia compared to MRI-only findings. CT-detected WMD may represent more advanced cerebrovascular injury, highlighting the need for modality-specific interpretation of incidentally discovered brain abnormalities.
Jun 10, 2026
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
May 21, 2026
Sentante secured CE-mark approval for its multi-domain robotic platform and was accepted into the FDA’s total product life cycle advisory programme. The moves support European commercialization and planning for remote stroke thrombectomy clinical studies.
May 04, 2026
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Apr 27, 2026
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
